The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC

For Immediate ReleasesChicago, IL – January 23, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include, Doximity DOCS, Omnicell OMCL, Embecta Corp. EMBC, Cencora, Inc. COR and the Global Telemedicine & Digital Health ETF EDOC.Here are highlights from Thursday’s Analyst Blog:4 MedTech Stocks Poised to Thrive Under Second Trump PresidencyTrump's return to the White House has introduced significant uncertainty for investors in the medical device industry. Major executive actions, including the U.S. withdrawal from the World Health Organization (WHO) and a freeze on federal regulatory activities, have sparked concerns among MedTech stakeholders. As investors await clarity, the initial environment under Trump 2.0 demands close monitoring of regulatory developments and adapting strategies to mitigate risks.Be that as it may, sectors like health IT, telemedicine and digital health platforms are witnessing growth opportunities and a positive outlook. Here, we have picked four Medtech stocks that are set to benefit from the new administrative policies. These are Doximity, Omnicell, Embecta Corp. and Cencora, Inc.Executive Orders Seemingly Putting MedTech in a Tight SpotExperts apprehend that exiting the WHO may reduce U.S. participation in global health initiatives, potentially limiting collaborative efforts in combating pandemics and advancing medical research. This withdrawal could also increase risks for medical device manufacturers that rely on international regulatory alignment and data-sharing facilitated by the WHO. This could potentially increase complexity in the regulatory approval process, costs and operational inefficiencies.Moreover, the freeze on regulatory activity under the FDA and CMS until new administration appointees approve policies has placed critical decisions in limbo, delaying new product approvals and reimbursement processes. For medical device companies, this uncertainty could hinder innovation timelines and revenue projections. The potential for slowed progress in approving breakthrough therapies and devices may discourage investments in early-stage startups and clinical trials.Silver Lining: Digital Health and Telemedicine Prospects BrightThe new administration repealed the former president’s Executive Order on AI safety. This strategic shift signals a strong positive impact on digital healthcare and telemedicine. Apparently, this will ease regulatory frameworks for these kinds of MedTech makers to test and deploy Gen AI applications more quickly, potentially giving U.S.-based firms a competitive edge in global AI markets. Meanwhile, telemedicine is expected to align with the administration's potential focus on improving healthcare access without expanding federal oversight.Since the Presidential inauguration on Jan. 20, the Global Telemedicine & Digital Health ETF has shown steady growth.4 MedTech Stocks to Keep An Eye OnDoximity: This leading digital platform for U.S. medical professionals is of late experiencing a significant increase in the use of its clinical workflow tool. The company is gaining success while providing its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits.This Zacks Rank #3 (Hold) company’s expected earnings growth rate for the third quarter of fiscal 2025 and full-year fiscal 2025 are 13.8% and 20%, respectively. Over the past six months, Doximity stock has risen 98.1%.Omnicell: As a major medication management solutions player, Omnicell is expected to garner success under Trump 2.0, banking on the company’s strategic investing in R&D efforts. This is expected to help drive positive medication management outcomes while ensuring advanced customer experience through a mature channel in four market categories. In terms of its financial roadmap, Omnicell targets to reach $1.9 billion-$2 billion of revenues by 2025, at a CAGR of 14%-15% through 2021-2025.This Zacks Rank #2 (Buy) company’s expected earnings growth rate for full-year 2025 is 6.1%. Over the past six months, Omnicell stock has surged 44.2%.Embecta: This global diabetes care company is expected to secure growth in 2025, banking on its advancement in providing solutions like pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.EMBC’s fiscal 2025 expected earnings growth rate is pegged at 15.9%. The stock carries a Zacks Rank #1 (Strong Buy) at present. Over the past six months, Embecta stock has gained 12.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.Cencora: This pharmaceutical services company focuses on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. Cencora is expected to benefit from generics growth in the long run. Strong organic growth rates in the U.S. pharmaceutical market, better patient access to care, improved economic conditions and population demographics, introduction of new innovative drugs like hepatitis C drugs, and a continued good brand pricing environment should drive growth in 2025.COR’s fiscal 2025 expected earnings growth rate is pegged at 8.9%. The stock carries a Zacks Rank #2 at present. Over the past six months, Cencora stock has risen 9%.Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.Today you can access their live picks without cost or obligation.See Stocks Free >>Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Media ContactZacks Investment Research800-767-3771 ext. 9339support@zacks.com                                     https://www.zacks.com                                                Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance  for information about the performance numbers displayed in this press release.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.1% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Omnicell, Inc. (OMCL): Free Stock Analysis Report Cencora, Inc. (COR): Free Stock Analysis Report Global X Telemedicine & Digital Health ETF (EDOC): ETF Research Reports Doximity, Inc. (DOCS): Free Stock Analysis Report Embecta Corp. (EMBC): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks